Weight Loss Drug Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Novo Nordisk Canada Moves to Keep Ozempic Affordable for Some Uninsured Patients

10 Obesity Drug Companies to Watch in 2026

GLP-1 Candidate Survodutide Shows Strong Weight Loss Results in Phase III Trials

Kailera Therapeutics IPO Raises $718.8M for Obesity Drug Pipeline

Foundayo (Orforglipron) Approval Adds Momentum in the Oral GLP-1 Space Against Rival Wegovy

Wegovy HD Receives FDA Approval as Fourth Product Under National Priority Voucher Program

New Zepbound Commercial “Watch This” Highlights Long-Term Impact

Underneath the Lost Kilos: Muscle Composition, Preservation and Function

World Obesity Day 2026: From Research Advances to Real-World Care

Roche CT-388 Phase II Obesity Trial Reports Weight-Loss Outcomes

January 28, 2026

New Zepbound TV Commercial Highlights $299 Self-Pay Option

January 26, 2026

Clinical Trial News

Aleniglipron Moves Toward Phase III as Structure Therapeutics Advances Oral GLP-1 Obesity Program

December 12, 2025

Next-Gen Obesity Trials: Redefining Efficacy, Lean Mass and Long-Term Outcomes

December 4, 2025

A Novel Approach to MASH Obesity Treatment: Weight Loss with Mitochondrial Science

Novo Nordisk’s Amycretin Moves to Phase III: What Sets This Obesity Drug Apart?

What’s the Latest Research in Weight Loss Medications Telling Us?

Next Page »